WE ARE TARGETING PAIN AT ITS SOURCE
VIRPAX Pharmaceuticals specializes in developing non-opioid based novel drug compounds and new drug delivery systems across various indications in order to increase compliance and maximize the ability to achieve full therapeutic efficacy.
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing non-opioid pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain.
VIRPAX has global rights to a patented metered-dose topical spray film delivery technology for musculoskeletal pain and osteoarthritis.
VIRPAX has worldwide rights to a patented injectable “local anesthetic” liposomal gel technology for postoperative pain management, as well as a patented long-acting liposomal “opioid antagonist” to reverse opioid related respiratory depression.
VIRPAX has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an Intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain.
VIRPAX® Pharmaceuticals is a privately held company located in West Chester, PA. and is focused on the development and commercialization of its non-addictive pipeline.
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic. VIRPAX will utilize our drug delivery technologies to develop a pipeline of proprietary prescription candidates for commercialization.
OUR MISSION
We develop branded non addictive pharmaceutical products for acute and chronic pain management using cutting-edge technology to enhance patients’ quality of life.
OUR VISION
We are focused on becoming the global leader in non-addictive pain management by developing innovative pharmaceutical products.
DEVELOPING OPTIONS
Our purpose is to provide healthcare professionals and patients with effective solutions to manage postoperative, acute and chronic pain, while helping prescribers facilitate better pain management outcomes worldwide.
TREATING MULTIPLE INDICATIONS
Our first-in-class transdermal spray film technology is being developed to manage acute and chronic pain musculoskeletal pain. Our proprietary spray film technology may also be developed to deliver other non-opioid molecules effective in treating central nervous system and inflammatory diseases.
EXPERIENCED
EXECUTIVE LEADERSHIP
ROBUST
PIPELINE
REINVENTING PAIN RELIEF
CHANGING THE WAY WE MANAGE PAIN
VIRPAX’s proprietary pipeline is well positioned to meet the unmet needs in a $36B market.
EpoladermTM will be the only metered-dose topical Diclofenac Epolamine spray film indicated for osteoarthritis of the knee.
VIRPAX will also introduce its proprietary ProbudurTM, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.
The FDA indicated that if Probudur demonstrated superior efficacy in comparison to Exparel in two or more clinical trials, the results of those studies could be reflected in a labeling claim.
RES202 (liposomal doxapram/naloxone) is being developed to reverse opioid side effects up to 48 hours; 47.5 hours longer than marketed Narcan®.
NES100 is being studied to manage moderate to severe acute and chronic pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
